Bioptimus Hits $76M Funding Milestone and Prepares to Launch Groundbreaking Foundation Model for Biology
Bioptimus has secured a total funding of $76 million, including a recent $41 million investment led by Cathay Innovation. The company, which successfully launched the world's largest AI foundation model for pathology (H-Optimus-0) in July, is preparing to release a breakthrough multi-scale, multi-modal foundation model for biology in 2025.
The H-Optimus-0 model has demonstrated superior performance in independent benchmarks, including evaluations by Harvard Medical School's HEST program and the University of Leeds, particularly in predicting gene expression from morphology and subtyping ovarian cancer.
The company aims to break down traditional research silos by integrating data across multiple scales (molecules, cells, tissues, organisms) and modalities (imaging, genetics, etc.). The funding will support platform enhancement, strategic partnerships with pharmaceutical and biotech companies, and dataset expansion.
Bioptimus ha ottenuto un finanziamento totale di 76 milioni di dollari, incluso un recente investimento di 41 milioni di dollari guidato da Cathay Innovation. L'azienda, che ha lanciato con successo il più grande modello fondazionale di IA al mondo per la patologia (H-Optimus-0) a luglio, si sta preparando a rilasciare un modello fondazionale multi-scala e multi-modale per la biologia nel 2025.
Il modello H-Optimus-0 ha dimostrato prestazioni superiori in benchmark indipendenti, inclusi i valutazioni da parte del programma HEST della Harvard Medical School e dell'Università di Leeds, in particolare nella previsione dell'espressione genica dalla morfologia e nella sottotipizzazione del cancro ovarico.
L'azienda mira a rompere i tradizionali silos di ricerca integrando dati su più scale (molecole, cellule, tessuti, organismi) e modalità (imaging, genetica, ecc.). Il finanziamento supporterà il miglioramento della piattaforma, le partnership strategiche con aziende farmaceutiche e biotecnologiche e l'espansione dei dataset.
Bioptimus ha conseguido un financiamiento total de 76 millones de dólares, incluido una reciente inversión de 41 millones de dólares liderada por Cathay Innovation. La empresa, que lanzó con éxito el mayor modelo de fundación de IA del mundo para patología (H-Optimus-0) en julio, se está preparando para liberar un innovador modelo de fundación multi-escala y multi-modal para biología en 2025.
El modelo H-Optimus-0 ha demostrado un rendimiento superior en benchmarks independientes, incluyendo evaluaciones del programa HEST de la Escuela de Medicina de Harvard y la Universidad de Leeds, especialmente en la predicción de la expresión génica a partir de la morfología y la subtipificación del cáncer de ovario.
La empresa busca romper los tradicionales silos de investigación integrando datos a través de múltiples escalas (moléculas, células, tejidos, organismos) y modalidades (imágenes, genética, etc.). La financiación apoyará la mejora de la plataforma, alianzas estratégicas con empresas farmacéuticas y biotecnológicas, y la expansión de conjuntos de datos.
Bioptimus는 7,600만 달러의 전 총 자금을 확보했으며, 최근에는 Cathay Innovation이 주도한 4,100만 달러의 투자를 포함합니다. 이 회사는 7월에 세계에서 가장 큰 병리학용 AI 기반 모델(H-Optimus-0)을 성공적으로 출시했으며, 2025년에는 생물학을 위한 멀티스케일, 멀티모달 기초 모델을 출시할 준비를 하고 있습니다.
H-Optimus-0 모델은 하버드 의대 HEST 프로그램과 리즈 대학교의 평가를 포함한 독립적인 벤치마크에서 우수한 성능을 보여주었으며, 특히 형태학을 통한 유전자 발현 예측과 난소암의 하위 유형화에서 두드러진 성과를 보였습니다.
회사는 데이터 통합 및 전통적인 연구 장벽을 허물기 위해 여러 스케일(분자, 세포, 조직, 유기체)과 모드(영상, 유전학 등)에서 데이터를 통합하는 것을 목표로 하고 있습니다. 이 자금은 플랫폼 개선, 제약 및 생명공학 회사와의 전략적 파트너십, 데이터 세트 확장에 활용될 예정입니다.
Bioptimus a obtenu un financement total de 76 millions de dollars, y compris un récent investissement de 41 millions de dollars dirigé par Cathay Innovation. L'entreprise, qui a lancé avec succès le plus grand modèle de fondation d'IA au monde pour la pathologie (H-Optimus-0) en juillet, se prépare à présenter un modèle de fondation révolutionnaire multi-échelle et multi-modal pour la biologie en 2025.
Le modèle H-Optimus-0 a démontré des performances supérieures dans des benchmarks indépendants, y compris des évaluations du programme HEST de la Harvard Medical School et de l'Université de Leeds, notamment dans la prédiction de l'expression génique à partir de la morphologie et la sous-typage du cancer de l'ovaire.
L'entreprise vise à briser les silos de recherche traditionnels en intégrant des données à travers plusieurs échelles (molécules, cellules, tissus, organismes) et modalités (imagerie, génétique, etc.). Le financement soutiendra l'amélioration de la plateforme, des partenariats stratégiques avec des entreprises pharmaceutiques et biotechnologiques, et l'expansion des jeux de données.
Bioptimus hat eine Gesamtfinanzierung von 76 Millionen Dollar gesichert, einschließlich einer kürzlichen Investition von 41 Millionen Dollar, die von Cathay Innovation geleitet wurde. Das Unternehmen, das erfolgreich das größte KI-Grundlagenmodell der Welt für Pathologie (H-Optimus-0) im Juli eingeführt hat, bereitet sich darauf vor, 2025 ein bahnbrechendes multimodales und multiplattformfähiges Grundlagenmodell für Biologie zu veröffentlichen.
Das H-Optimus-0-Modell hat in unabhängigen Benchmarks überlegene Leistungen gezeigt, darunter Bewertungen des HEST-Programms der Harvard Medical School und der Universität Leeds, insbesondere bei der Vorhersage der Genexpression aus Morphologie und der Subtypisierung von Eierstockkrebs.
Das Unternehmen zielt darauf ab, traditionelle Forschungssilos zu durchbrechen, indem es Daten über mehrere Skalen (Moleküle, Zellen, Gewebe, Organismen) und Modalitäten (Bildgebung, Genetik usw.) integriert. Die Finanzierung wird die Verbesserung der Plattform, strategische Partnerschaften mit pharmazeutischen und biotechnologischen Unternehmen sowie die Erweiterung von Datensätzen unterstützen.
- Secured substantial funding of $76M, with recent $41M investment
- Successfully launched world's largest AI foundation model for pathology
- Demonstrated superior performance in independent benchmarks
- Strong investor backing from prominent institutions
- New foundation model not launching until 2025
- Requires significant additional data collection and validation
Insights
The
The H-Optimus-0 pathology model's superior performance in Harvard and Leeds benchmarks demonstrates clear technological differentiation. The planned multi-scale, multi-modal foundation model could be a game-changer for drug discovery and development, potentially reducing R&D costs and accelerating time-to-market for new therapeutics.
While not publicly traded, this development has broader implications for the biotech sector, particularly companies focused on AI-driven drug discovery like Recursion Pharmaceuticals and Schrödinger. The validation of AI foundation models in biology could accelerate industry-wide adoption and reshape traditional R&D approaches.
The development of a biology-focused foundation model represents a significant technological leap, analogous to GPT's impact on language processing. The multi-scale, multi-modal approach addresses a critical limitation in current biological AI models by integrating various data types and scales, from molecular to organism level.
The successful deployment of H-Optimus-0 for pathology, with validated superior performance in predicting gene expression and cancer subtyping, establishes a strong proof-of-concept. The planned 2025 release of their comprehensive biology model could create new opportunities in personalized medicine, drug development and biological engineering.
This advancement could particularly benefit companies in the computational biology and AI healthcare sectors, potentially accelerating drug discovery timelines and reducing development costs through more accurate biological simulations.
-
Bioptimus announces a
$76M $41M
- Since the successful release of the largest AI foundation model for pathology in July, the company has been continuing its groundbreaking work and is now poised to release a breakthrough new multi-scale, multi-modal foundation model for biology in 2025
- The new model will allow the simulation of biology at unprecedented scale and dimension, creating biological innovation for medical, biotech, cosmetic industries, and beyond
The company has been building momentum this year, assembling a world-class team, securing access to unique data sources, and successfully releasing its first model, H-Optimus-0, the world’s largest foundation model for pathology. H-Optimus-0 has already outperformed all other pathology models in independent benchmarks, including assessments conducted by Harvard Medical School’s HEST program1 and the University of Leeds.2 These studies highlighted the model’s unparalleled ability to predict gene expression from morphology and to subtype ovarian cancer with exceptional accuracy.
Breaking Down Silos in Biology
Bioptimus is redefining how we approach biological research by addressing a longstanding issue: the siloed nature of biological understanding. Historically, research has focused on isolated biological components, such as DNA, proteins, cells or tissues. Even existing AI foundation models operate within these silos, limiting their potential impact. Bioptimus’s revolutionary approach integrates data across multiple scales (molecules, cells, tissues, organisms) and modalities (imaging, genetics, etc), enabling a holistic view of biology as it exists in reality.
Jean-Philippe Vert, co-founder and CEO of Bioptimus, stated: “What we are building is not just a technological breakthrough; it’s a transformative tool for understanding biology in its full complexity. By learning how biology works directly from raw data across scales, from molecules to whole organisms, our model will empower researchers in the pharmaceutical industry to simulate complex biology, predict disease outcomes and response to treatment, and design therapies with unprecedented precision. Beyond pharmaceuticals, this model will unlock limitless possibilities across many other industries, driving biological discoveries in ways we are only beginning to imagine. Essentially, it’s like the GPT of biology—but instead of generating text, we’re simulating biology.”
The funding will enable Bioptimus to enhance its multi-modal AI platform, integrating even more diverse data sources and therapeutic areas, forge strategic partnerships with pharmaceutical and biotech companies and expand critical datasets to further refine and validate its models.
Jacky Abitbol, Partner at Cathay Innovation, said: "Bioptimus is at the forefront of transforming biological research, leveraging cutting-edge AI to break down silos and unlock the full complexity of biology. By integrating data across multiple scales and modalities, Bioptimus is paving the way for groundbreaking innovations across industries, from pharmaceuticals to biotechnology and beyond. We are delighted to see that since our initial investment a year ago, Bioptimus has succeeded in structuring a world-class team, while achieving key milestones in its development, notably with the launch of its AI foundation model for pathology in July, the largest in the world."
By combining the power of AI with a truly integrated view of biology, Bioptimus will empower researchers and multiple industries to solve some of the most complex challenges in medicine, biotechnology, and beyond.
For more information, visit bioptimus.com.
About Cathay Innovation
Cathay Innovation is a multistage venture capital firm, affiliated to Cathay Capital, investing in founders building transformative businesses across
To learn more, visit us at www.cathayinnovation.com or follow us on LinkedIn or Twitter @cathayinnov.
| ____________________________________ |
1 Mahmood Lab, 2024. HEST: Hierarchical Embedding of Spatial Transcriptomics. Available at: https://github.com/mahmoodlab/HEST |
2 Arxiv.org, 2024. A New Model for Data Processing in Neural Networks. Available at: https://arxiv.org/abs/2405.09990 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250114054102/en/
Media Contact: press@bioptimus.com
Source: Bioptimus
FAQ
What is the total funding raised by Bioptimus in its latest round?
When will Bioptimus launch its new biology foundation model?
What are the key achievements of Bioptimus's H-Optimus-0 model?
Who are the main investors in Bioptimus's latest funding round?
What is the main goal of Bioptimus's new foundation model?
